Pediatric Neuro-Oncology Tumor Board Series (July 20, 2022)

Needs Statement

Faculty, fellows, residents, and other healthcare professionals in pediatric neuro-oncology need to receive regular updates regarding advances in the multi-disciplinary strategies used to treat brain and other central nervous system tumors in children. The tumor board aims to increase knowledge of the learners in the topic areas discussed, and encourages learners to implement current clinical practice guidelines and advanced treatment strategies to enhance the quality of patient care and outcomes.

Educational Objectives

At the conclusion of the sessions, the participants should be able to:

• Examine the importance of an integrated multi-disciplinary approach to the management of children with brain tumors and incorporate into clinical practice.
• Explain the rationale for specific tests for the diagnosis and management of pediatric brain tumors.
• Discuss the design of various phases of clinical trials, and compare the significance of early phase clinical trials versus phase 3 clinical trials.
• Evaluate the various therapeutic interventions for brain tumors, particularly with reference to neurosurgery, chemotherapy, and radiation therapy.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.